Yescarta®(axicabtagene ciloleucel) – Expanded indication
April 1, 2022 - Gilead announced the FDA approval of Yescarta (axicabtagene ciloleucel), for the treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
Top